Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.

Adds speed and agility with cGMP production at on-site pharmacies, adds capacity, improves flexible therapeutic capabilities and enhances experience for study volunteers

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed a multi-year effort to expand its clinical pharmacology solutions and capacity, which are now fully available for customers. The expansion includes a 100,000 square feet state-of-the-art facility in Leeds, U.K. as well as approximately 20,000 square feet of new or renovated space, adding capacity and capabilities across its clinical research units (CRUs) in Dallas, Texas; Daytona, Florida; and Madison, Wisconsin.

“The increasing complexity of clinical pharmacology studies demands fit-for-purpose infrastructure, experience and expertise to protect the safety of study participants and the integrity of critically important data,” said Oren Cohen, M.D., Fortrea’s president of Clinical Pharmacology and chief medical officer. “Our integrated platform of services includes best-in-class infrastructure and experienced professionals who are fully dedicated to clinical pharmacology, including physicians, nurses, clinical scientists, CRAs and pharmacokineticists. The investments we have made target the capabilities and capacity that customers need to accurately assess early pipeline candidates and speed those with promise to later-phase development and ultimately to patients who need them.”

Facility enhancements following the completed expansion include Fortrea’s new CRU in Leeds as well as purpose-built rooms in Madison and Daytona designed for flexibility in executing complex early phase clinical studies. Improvements in recreational, living and “work-from-home” spaces at Fortrea CRUs have been constructed to enhance the experience of volunteers participating in research at the sites.

The expansion of Fortrea’s early clinical development pharmacy services facilities includes new state-of-the-art cGMP pharmacies in the Leeds and Daytona CRUs. All Fortrea CRUs will now have cGMP pharmacies within them. This enables on-site manufacture of sterile and non-sterile drug product. The design of its GMP-compliant facilities provides safe handling and delivery of GMP-quality drug product for the unique demands of clinical pharmacology studies, focusing on efficiency and flexibility with the level of controls expected by regulatory authorities and sponsors.

Enhancements in science and technology include the addition of artificial intelligence-enabled programs that optimize bed space utilization and clinic scheduling, and the application of failure modes and effects analysis to de-risk study execution before a study begins. Following investments in data collection systems, all clinical pharmacology study data collected within Fortrea’s CRUs are input directly into a digital bedside data capture system, which can also be used as an efficient electronic data capture solution.

“I believe Fortrea’s early clinical development solutions set a new standard for what the research industry should expect from its partners,” said Dr. Cohen. “I’m so proud of this team and know they will also benefit from the changes we have made. Just as they are inspired by our mission of bringing life-changing treatments to patients faster, I’m inspired by their dedication each day as we deliver solutions to our customers.”

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services.

Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements in this press release, particularly those relating to the anticipated financial and other benefits, including, but not limited to, whether the investments at clinical research units in U.S. and U.K. will add capacity, improve therapeutic capabilities, enhance experience for study volunteers, speed development to later-phase trials and improve the integrity of data and whether the addition of artificial intelligence-enabled programs will optimize bed space utilization and clinic scheduling, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from expectations expressed or implied in the forward-looking statements if one or more of the underlying assumptions or expectations prove to be inaccurate or are unrealized. Important factors that could cause actual results to differ materially from such expectations are and will be detailed in Fortrea’s registration statement on Form 10 initially filed with the SEC on May 15, 2023 (as amended and further supplemented), Fortrea’s quarterly report on Form 10-Q filed with the SEC on August 14, 2023, and in Fortrea’s other filings with the SEC. These forward-looking statements are based on management’s current expectations and are subject to certain risks, uncertainty and changes in circumstances. Fortrea does not undertake responsibility for updating these statements, and these statement speak only as of the date of this press release.

Fortrea Contacts:

Fortrea Media: Sue Zaranek – 919-943-5422, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com
Fortrea Investors: Hima Inguva – 877-495-0816, hima.inguva@fortrea.com

GlobeNewswire Distribution ID 8971131

Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.

Adds speed and agility with cGMP production at on-site pharmacies, adds capacity, improves flexible therapeutic capabilities and enhances experience for study volunteers

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed a multi-year effort to expand its clinical pharmacology solutions and capacity, which are now fully available for customers. The expansion includes a 100,000 square feet state-of-the-art facility in Leeds, U.K. as well as approximately 20,000 square feet of new or renovated space, adding capacity and capabilities across its clinical research units (CRUs) in Dallas, Texas; Daytona, Florida; and Madison, Wisconsin.

“The increasing complexity of clinical pharmacology studies demands fit-for-purpose infrastructure, experience and expertise to protect the safety of study participants and the integrity of critically important data,” said Oren Cohen, M.D., Fortrea’s president of Clinical Pharmacology and chief medical officer. “Our integrated platform of services includes best-in-class infrastructure and experienced professionals who are fully dedicated to clinical pharmacology, including physicians, nurses, clinical scientists, CRAs and pharmacokineticists. The investments we have made target the capabilities and capacity that customers need to accurately assess early pipeline candidates and speed those with promise to later-phase development and ultimately to patients who need them.”

Facility enhancements following the completed expansion include Fortrea’s new CRU in Leeds as well as purpose-built rooms in Madison and Daytona designed for flexibility in executing complex early phase clinical studies. Improvements in recreational, living and “work-from-home” spaces at Fortrea CRUs have been constructed to enhance the experience of volunteers participating in research at the sites.

The expansion of Fortrea’s early clinical development pharmacy services facilities includes new state-of-the-art cGMP pharmacies in the Leeds and Daytona CRUs. All Fortrea CRUs will now have cGMP pharmacies within them. This enables on-site manufacture of sterile and non-sterile drug product. The design of its GMP-compliant facilities provides safe handling and delivery of GMP-quality drug product for the unique demands of clinical pharmacology studies, focusing on efficiency and flexibility with the level of controls expected by regulatory authorities and sponsors.

Enhancements in science and technology include the addition of artificial intelligence-enabled programs that optimize bed space utilization and clinic scheduling, and the application of failure modes and effects analysis to de-risk study execution before a study begins. Following investments in data collection systems, all clinical pharmacology study data collected within Fortrea’s CRUs are input directly into a digital bedside data capture system, which can also be used as an efficient electronic data capture solution.

“I believe Fortrea’s early clinical development solutions set a new standard for what the research industry should expect from its partners,” said Dr. Cohen. “I’m so proud of this team and know they will also benefit from the changes we have made. Just as they are inspired by our mission of bringing life-changing treatments to patients faster, I’m inspired by their dedication each day as we deliver solutions to our customers.”

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services.

Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements in this press release, particularly those relating to the anticipated financial and other benefits, including, but not limited to, whether the investments at clinical research units in U.S. and U.K. will add capacity, improve therapeutic capabilities, enhance experience for study volunteers, speed development to later-phase trials and improve the integrity of data and whether the addition of artificial intelligence-enabled programs will optimize bed space utilization and clinic scheduling, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from expectations expressed or implied in the forward-looking statements if one or more of the underlying assumptions or expectations prove to be inaccurate or are unrealized. Important factors that could cause actual results to differ materially from such expectations are and will be detailed in Fortrea’s registration statement on Form 10 initially filed with the SEC on May 15, 2023 (as amended and further supplemented), Fortrea’s quarterly report on Form 10-Q filed with the SEC on August 14, 2023, and in Fortrea’s other filings with the SEC. These forward-looking statements are based on management’s current expectations and are subject to certain risks, uncertainty and changes in circumstances. Fortrea does not undertake responsibility for updating these statements, and these statement speak only as of the date of this press release.

Fortrea Contacts:

Fortrea Media: Sue Zaranek – 919-943-5422, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com
Fortrea Investors: Hima Inguva – 877-495-0816, hima.inguva@fortrea.com

Colonists Storm Al-Aqsa Mosque, Occupation Police Tighten Military Measures

Occupied Jerusalem, – Dozens of Israeli colonists stormed the blessed Al-Aqsa Mosque compound on Thursday morning under the protection of Israeli occupation forces.

The colonists stormed the mosque from the Mughrabi Gate, toured its courtyards and performed Talmudic rituals in the vicinity of Bab Al-Rahma prayer hall, the Palestinian News Agency (WAFA) quoted worshipers in the mosque as saying The occupation police tightened their military measures around Al-Aqsa Mosque.

Source: Qatar News Agency

State of Qatar Affirms Support for UNHCR

New York, – The State of Qatar affirmed its support for the efforts of the United Nations High Commissioner for Refugees (UNHCR), praising its indispensable role in addressing the crises and suffering of millions of refugees around the world.

This came in the State of Qatar’s statement, which was delivered by member of the State of Qatar’s delegation to the 78th session of the United Nations General Assembly Saleh Mohammed Al Khayarin, before the Third Committee during the discussion with those charged with thematic mandates within the framework of special procedures, specifically the UNHCR at the UN headquarters in New York.

Al Khayarin welcomed the participation of the United Nations High Commissioner for Refugees Filippo Grandi and expressed his appreciation for him for his report that was presented to the Committee, adding that the State of Qatar highly appreciates the great responsibility placed on the shoulders of the United Nations High Commissioner for Refugees and the pioneering role played by the Commission, especially in light of the growing and widespread level of displacement in various parts of the world as a result of the increasing rate of humanitarian crises, conflicts, violence, climate risks, and other issues, and the challenges and concerns this poses for the international community.

The statement indicated that in light of the scale of the current displacement challenges, and the need to respond more effectively to emerging and different requirements, the State of Qatar considers what the report indicated regarding the need to redouble efforts to find solutions important, in addition to the critical importance of responses to the global movement that take into account human rights.

He added that the State of Qatar has always been one of the countries that provides aid and support to refugees, displaced persons, and host countries, and it will continue to play a leading role in providing humanitarian aid to refugees, such as the humanitarian aid provided by the State of Qatar in response to the crisis in Syria, and supporting projects to deal with winter for Syrian refugees in both Jordan and Lebanon, in addition to the mediation and preventive diplomacy efforts undertaken by the State of Qatar, which constitute a preventive support factor to mitigate the severity of conflicts and crises.

The statement stressed that the State of Qatar values the close and strategic partnership with the UNHCR and is pleased that this vital cooperation and distinguished partnership has culminated in the opening of an office for the UNHCR in the United Nations House that was inaugurated last March in Doha, which includes offices of a number of United Nations agencies.

He added that the State of Qatar also provides vital support to the efforts of the Commission and enables it to provide support to those who need it most; for example, Qatar provided unallocated contributions amounting to $16 million for the period 2019-2020, in addition to $8 million for the period 2021-2022. He stressed that the State of Qatar will continue its efforts to strengthen the capacity of the Commission and provide support for basic resources with a total of $8 million for the period 2023-2024.

Source: Qatar News Agency

Lebanese Caretaker Prime Minister Meets Qatari Ambassador

Beirut, November 2 – HE Caretaker Prime Minister of the Republic of Lebanon Najib Mikati met Thursday with HE Ambassador of the State of Qatar to Lebanon Sheikh Saud bin Abdulrahman Al-Thani.

During the meeting, bilateral cooperation relations between the two countries were discussed.

Source: Qatar News Agency

International Day to End Impunity for Crimes against Journalists… Report

Doha, – Journalism is one of the most dangerous and courageous professions, dedicated to seeking the truth and conveying reality without distortion or propaganda.

The primary function of the media faces numerous obstacles, including threats and crimes that may endanger lives, in addition to restrictions, lack of cooperation, prevention, closure, revocation of media licenses, and misuse of judicial systems in arbitrary ways to target journalists who oppose oppression, murder, kidnapping, torture, and illegal practices.

Therefore, access to information and a complete understanding of events and their implications are at stake, because this affect the work environment.

Latin America and the Caribbean continues to be the region with the highest number of murders of journalists, according to the 2022 UNESCO Director-Generals Report on the Safety of Journalists and the Danger of Impunity. Since 1993, more than 1,600 journalists have been killed for reporting the news and bringing information to the public. In nine out of ten cases the killers go unpunished, according to the UNESCO observatory of killed journalists. Impunity leads to more killings and is often a symptom of worsening conflict and the breakdown of law and judicial systems.

The past two years have seen Latin America and the Caribbean (45 killings), and Asia and the Pacific (38 killings) continue to record the largest number of journalist killings according to UNESCO data. In 2020-2021, Latin America and the Caribbean accounted for 38% of killings, followed by Asia and the Pacific with 32% of killings.

The UNESCO publishes an international report on journalist safety and impunity levels every six months, through local reports provided by the 39 Member States of the International Programme for the Development of Communication. Though it remains unacceptably high, impunity for crimes committed against journalists has continuously decreased, by a total of 3% since 2018, the first year of the previous biennium. In 2022, the global impunity rate was measured by UNESCO at 86% compared to 89% in 2018.

In 2020-2021, UNESCO recorded a total of 117 killings of journalists worldwide. Overall, the 2020-2021 biennium saw the lowest number of deaths than any other reporting period since the first publication of this Report in 2008. The year 2021 shows the lowest annual death toll in 14 years with 55 killings. However, it is important to highlight that, although outside of this reporting period, according to the UNESCO’s Observatory of Killed Journalists, this number has risen a total of 87 killed journalists in 2022.

Thus, ending impunity for crimes against journalists is one of the most challenging issues in recent years. International efforts aim to raise awareness of the major challenges faced by journalists and media workers during the performance of their duties. Women journalists are particularly impacted by threats and attacks, notably by those made online. According to UNESCOs discussion paper, The Chilling: Global trends in online violence against women journalists, 73 percent of the women journalists surveyed said they had been threatened, intimidated and insulted online in connection with their work. (MORE)

Source: Qatar News Agency